We are a clinical-stage pharmaceutical company developing novel therapeutics in metabolic diseases, focusing on non-alcoholic steatohepatitis (NASH), and oncology. Emphasis on these disease areas originates from our expertise with the fatty acid synthase enzyme (FASN) and its central role in multiple diseases.
Our lead product candidate, TVB-2640, is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN. We have tested this drug both as monotherapy and in combination with paclitaxel in a Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast cancer, and ovarian cancer. This Phase 1 study showed that the drug was well absorbed, entered the bloodstream of these patients, and inhibited their FASN activity, resulting in reduced de novo lipogenesis (DNL). Having shown that TVB-2640 reduces lipogenesis in patients with cancer, we are currently collaborating with investigators at the University of Missouri to evaluate the dose of TVB-2640 required to reduce liver fat synthesis in healthy individuals with characteristics of metabolic syndrome.